Hosted on MSN2mon
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
Fierce Pharma4h
Manufacturing issues trip up Milestone's long-awaited FDA landmark
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Yahoo Finance7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...
pharmaphorum2mon
J&J's Spravato gets another lift with new FDA approval
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ... Spravato administered as a nasal spray achieved a rapid and ...
Healio22d
FDA approves epinephrine nasal spray for children aged as young as 4 years
Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...
Nasdaq15d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Milestone Pharmaceuticals Inc. announced that the FDA has ... for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). If approved, Milestone ...
Benzinga.com22d
3SPRY : FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray...
FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Feel unsure about ...
Pharm Exec7d
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
The FDA has approved Johnson & Johnson’s (J&J) Tremfya (guselkumab) for the treatment of moderately to severely active Crohn disease (CD). The regulatory action makes Tremfya the first and only ...
Benzinga.com7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
FDA approved Johnson & Johnson’s Tremfya as the first IL-23 inhibitor with both SC and IV induction options for Crohn’s disease. Tremfya sales reached $3.67 billion in 2024, marking a 17% year ...
Yahoo Finance7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV ...